William K. Oh, MD

William K. Oh, MD, an expert in the management of genitourinary (GU) malignancies, is clinical professor of medicine in the Division of Hematology and Medical Oncology at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai. Dr Oh graduated from Yale College with a BS in molecular biophysics and biochemistry, and he received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital and his medical oncology fellowship at the Dana-Farber Cancer Institute in 1997.

From 2009 to 2020, Dr Oh was system chief of hematology and medical oncology at the Mount Sinai Health System; the Ezra Greenspan, MD Professor in Clinical Cancer Therapeutics; and associate and deputy director of The Tisch Cancer Institute at Mount Sinai, for which he helped to achieve and renew National Cancer Institute designation. Prior to that, he spent 14 years at Harvard Medical School and Dana-Farber Cancer Institute, including as clinical director of GU oncology, associate professor of medicine, director of the Arthur and Linda Gelb Center for Translational Research, and founding chair of the Dana-Farber/Harvard Cancer Center Data and Safety Monitoring Committee.

Dr Oh was recently the inaugural chief medical officer at Prostate Cancer Foundation, where he built an implementation science platform to address prostate cancer mortality, resulting in the publication of the first-ever “Prostate Cancer Foundation Screening Guidelines for Black Men in the United States” in NEJM Evidence in 2024. From 2021 to 2022, he was chief medical science officer at Sema4, a publicly traded, patient-centered health intelligence company that used genomics and real-world evidence/artificial intelligence (AI) to develop algorithms to improve rare disease and cancer care. At Sema4, Dr Oh launched clinical protocols and health system partnerships to improve the understanding of genomic testing by tying molecular insights to clinical data extracted by machine learning/AI from electronic health records.

He is founding chair of the scientific advisory board of Archetype Therapeutics, a startup using a novel AI-generated modeling platform to screen billions of drugs to predict the best candidates for unmet medical needs in cancer. He is also chair of the SAB for NTx Bio, a biomanufacturing startup building systems to produce personalized mRNA vaccines in sustainable, scalable devices. He serves as board member and chair of the for the Chemotherapy+ Foundation Medical Advisory Council in New York City.

Dr Oh has authored more than 350 original articles, reviews, and chapters, and he has edited 3 books on prostate cancer. He has served in key roles for the American Society of Clinical Oncology, the American Cancer Society, the American Urological Association, and the American Joint Committee on Cancer. He is an inductee of the American Society for Clinical Investigation, and he has been continuously selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors, and Super Doctors from 2010 to 2024. He has also been honored as a Top AAPI Doctor in 2023 and 2024.